- Home
- RIGL vs ALLO Comparison
RIGL vs ALLO Comparison
Compare RIGL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ALLO
- Stock Information
- Founded
- RIGL 1996
- ALLO 2017
- Country
- RIGL United States
- ALLO United States
- Employees
- RIGL N/A
- ALLO N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIGL Health Care
- ALLO Health Care
- Exchange
- RIGL Nasdaq
- ALLO Nasdaq
- Market Cap
- RIGL 334.5M
- ALLO 371.8M
- IPO Year
- RIGL 2000
- ALLO 2018
- Fundamental
- Price
- RIGL $18.28
- ALLO $0.95
- Analyst Decision
- RIGL Buy
- ALLO Strong Buy
- Analyst Count
- RIGL 5
- ALLO 10
- Target Price
- RIGL $36.40
- ALLO $9.30
- AVG Volume (30 Days)
- RIGL 205.1K
- ALLO 3.8M
- Earning Date
- RIGL 05-06-2025
- ALLO 05-13-2025
- Dividend Yield
- RIGL N/A
- ALLO N/A
- EPS Growth
- RIGL N/A
- ALLO N/A
- EPS
- RIGL 2.08
- ALLO N/A
- Revenue
- RIGL $203,077,000.00
- ALLO N/A
- Revenue This Year
- RIGL $24.45
- ALLO N/A
- Revenue Next Year
- RIGL $7.23
- ALLO $9.07
- P/E Ratio
- RIGL $8.77
- ALLO N/A
- Revenue Growth
- RIGL 70.16
- ALLO N/A
- 52 Week Low
- RIGL $7.48
- ALLO $1.09
- 52 Week High
- RIGL $29.82
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- RIGL 47.44
- ALLO 25.48
- Support Level
- RIGL $17.65
- ALLO $1.09
- Resistance Level
- RIGL $19.75
- ALLO $1.28
- Average True Range (ATR)
- RIGL 1.46
- ALLO 0.15
- MACD
- RIGL -0.02
- ALLO -0.05
- Stochastic Oscillator
- RIGL 16.39
- ALLO 9.88
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.